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COPD: Optimizing Treatment 
Abstract 
A guideline update and an expanded armamentarium have many physicians wondering how best to treat 
patients with COPD. Chronic obstructive pulmonary disease (COPD) carries a high disease burden. In 
2012, it was the 4th leading cause of death worldwide.1,2 In 2015, the World Health Organization updated 
its Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, classifying patients with 
COPD based on disease burden as determined by symptoms, airflow obstruction, and exacerbation 
history.3 These revisions, coupled with expanded therapeutic options within established classes of 
medications and new combination drugs to treat COPD (TABLE 1),3-6 have led to questions about 
interclass differences and the best treatment regimen for particular patients. 
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A guideline update and an expanded armamentarium 
have many physicians wondering how best to treat 
patients with COPD. Here’s help.
Chronic obstructive pulmonary disease (COPD) carries a high disease burden. In 2012, it was the 4th lead-ing cause of death worldwide.1,2 In 2015, the World 
Health Organization updated its Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines, classifying pa-
tients with COPD based on disease burden as determined by 
symptoms, airflow obstruction, and exacerbation history.3 
These revisions, coupled with expanded therapeutic options 
within established classes of medications and new combina-
tion drugs to treat COPD (TABLE 1),3-6 have led to questions 
about interclass differences and the best treatment regimen 
for particular patients.
Comparisons of various agents within a therapeutic 
class and their impact on lung function and rate of exac-
erbations address many of these concerns. In the text and 
tables that follow, we present the latest evidence highlight-
ing differences in dosing, safety, and efficacy. We also in-
clude the updated GOLD classifications, evidence of efficacy 
for pulmonary rehabilitation, and practical implications of 
these findings for the optimal management of patients 
with COPD. 
But first, a word about terminology. 
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PrACTiCE 
rECoMMENDATioNS
› Individualize treatment 
regimens based on  
severity of symptoms and risk 
for exacerbation, prescribing 
short-acting beta
2
-agonists, as 
needed, for all patients with 
chronic obstructive  
pulmonary disease 
(COPD).  A
› Limit use of inhaled 
long-acting beta
2
-agonists to 
the recommended dosage; 
higher doses do not lead 
to better outcomes.  A
Strength of recommendation (Sor)
  Good-quality patient-oriented 
evidence
  Inconsistent or limited-quality 
patient-oriented evidence
  Consensus, usual practice,  
opinion, disease-oriented  
evidence, case series
A
B
C
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Understanding CoPD
COPD is a chronic lung disease character-
ized by progressive airflow limitation, usu-
ally measured by spirometry (TABLE 2),3 and 
chronic airway inflammation. Emphysema 
and chronic bronchitis are often used syn-
onymously with COPD. In fact, there are im-
portant differences. 
Individuals with chronic bronchitis do 
not necessarily have the airflow limitations 
found in those with COPD. And patients with 
COPD develop pathologic lung changes be-
yond the alveolar damage characteristic of 
emphysema, including airway fibrosis and 
inflammation, luminal plugging, and loss of 
elastic recoil.3
The medications included in this review 
aim to reduce both the morbidity and mor-
tality associated with COPD. These drugs can 
also help relieve the symptoms of patients 
with chronic bronchitis and emphysema, but 
have limited effect on patient mortality. 
Short- and long-acting 
beta2-agonists  
Bronchodilator therapy with beta
2
-agonists 
improves forced expiratory volume in one 
second (FEV
1
) through relaxation of airway 
smooth muscle. Beta
2
-agonists have proven 
to be safe and effective when used as needed 
or scheduled for patients with COPD.7  
Inhaled short-acting beta
2
-agonists 
(SABAs) improve FEV
1
 and symptoms with-
in 10 minutes, with effects lasting up to 4 to 
6 hours; long-acting beta
2
-agonists (LABAs) 
have a variable onset, with effects lasting 12 to 
24 hours.8  Inhaled levalbuterol, the last SABA 
to receive US Food and Drug Administration 
approval, has not proven to be superior to 
conventional bronchodilators in ambulatory 
patients with stable COPD.3 In clinical trials, 
however, the slightly longer half-life of the 
nebulized formulation of levalbuterol was 
found to reduce both the frequency of ad-
ministration and the overall cost of therapy 
in patients hospitalized with acute exacerba-
tions of COPD.9,10 
recently approved LABAs 
Clinical trials have studied the safety and 
efficacy of newer agents vs older LABAs in 
patients with moderate to severe COPD. 
Compared with theophylline, for example, 
formoterol 12 mcg inhaled every 12 hours 
for a 12-month period provided a clini-
cally significant increase of >120 ml in FEV
1
 
(P=.026).11 Higher doses of formoterol did not 
provide any additional improvement. 
In a trial comparing indacaterol and 
tiotropium, an inhaled anticholinergic, both 
treatment groups had a clinically significant 
increase in FEV
1
, but patients receiving in-
dacaterol achieved an additional increase of 
40 to 50 mL at 12 weeks.12
Exacerbation rates for all LABAs range 
from 22% to 44%.5,12,13 In a study of patients 
receiving formoterol 12 mcg compared with 
15-mcg and 25-mcg doses of arformoterol, 
those taking formoterol had a lower exacer-
bation rate than those on either strength of 
arformoterol (22% vs 32% and 31%, respec-
tively).10 In various studies, doses greater 
than the FDA-approved regimens for inda-
caterol, arformoterol, and olodaterol did not 
result in a significant improvement in either 
FEV
1
 or exacerbation rates compared with 
placebo.5,12,14
Studies that assessed the use of rescue 
medication as well as exacerbation rates in 
patients taking LABAs reported reductions 
in the use of the rescue drugs ranging from 
0.46 to 1.32 actuations per day, but the find-
ings had limited clinical relevance.5,13 With 
the exception of indacaterol and olodaterol—
both of which may be preferable because of 
their once-daily dosing regimen—no signifi-
cant differences in safety and efficacy among 
LABAs have been found.5,12,13
Long-acting inhaled  
anticholinergics
Inhaled anticholinergic agents (IACs) can 
be used in place of, or in conjunction with, 
LABAs to provide bronchodilation for up to 
24 hours.3 The introduction of long-acting 
IACs dosed once or twice daily has the poten-
tial to improve medication adherence over 
traditional short-acting ipratropium, which 
requires multiple daily doses for symptom 
control. Over 4 years, tiotropium has been 
shown to increase time to first exacerbation 
by approximately 4 months. It did not, how-
Exacerbation 
rates for all 
long-acting  
beta2-agonists 
range from 22% 
to 44%. 
conTinued on PaGe 617
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ever, significantly reduce the number of exac-
erbations compared with placebo.15 
Long-term use of tiotropium appears to 
have the potential to preserve lung function. 
In one trial, it slowed the rate of decline in 
FEV
1
 by 5 mL per year, but this finding lacked 
clinical significance.13 In clinical trials of pa-
tients with moderate to severe COPD, howev-
er, once-daily tiotropium and umeclidinium 
provided clinically significant improvements 
in FEV
1
 (>120 mL; P<.01), regardless of the 
dose administered.6,16 In another trial, pa-
tients taking aclidinium 200 mcg or 400 mcg 
every 12 hours did not achieve a clinically sig-
TABLE 1  
COPD: Assessing newer inhaled treatments3-6
drug/dose (trade name) dosing  
frequency 
(hours)
evidence
laBas
arformoterol  
15 mcg/2 ml solution for 
nebulization (Brovana)
12 evidence level not assessed in current guidelines  
nebulized arformoterol mdi resulted in a clinically 
significant higher % change in feV1 vs salmeterol
Slightly higher exacerbation rates with arformoterol 
than with formoterol
indacaterol dPi 75 mcg 
(arcapta neohaler)
24 Bronchodilator effect greater than salmeterol and  
formoterol; similar to tiotropium 
decreases breathlessness and exacerbations, improves 
overall health status
long-acting iacs
aclidinium bromide  
400 mcg dPi (Tudorza  
Pressair)
12 evidence level not determined in current guidelines, but 
statement notes that aclidinium is similar to tiotropium 
for lung function and shortness of breath
Tiotropium  
17 mcg dPi (Spiriva  
handihaler) 
24 reduces exacerbations and hospitalizations, improves 
symptoms and effectiveness of pulmonary rehabilitation
umeclidinium bromide  
62.5 mcg dPi (incruse ellipta)
24 not assessed in current guidelines; active comparator 
trials pending  
compared with placebo, umeclidinium resulted in  
clinically significant improvements in feV1
combinations 
icS + laBa 
fluticasone + vilanterol 
100/25 dPi  
(Breo ellipta)
24 icS + a laBa or long-acting iac is more effective than 
individual components in improving lung function and 
health status in patients with moderate to very severe 
coPd
combination therapy is associated with an increased 
risk of pneumonia, but with no other significant  
adverse effects 
laBa + iac
umeclidinium + vilanterol  
62.5/25 dPi   
(anoro ellipta) 
24 not assessed in current guidelines
Product improved lung function vs monotherapy with 
vilanterol 
coPd, chronic obstructive pulmonary disease; dPi, dry powder inhaler; iac, inhaled anticholinergic agent; icS, inhaled  
corticosteroid; laBa, long-acting beta2-agonist; mdi, metered dose inhaler (aerosol).
COPD
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nificant improvement in FEV
1
 compared with 
placebo.17
In patients with moderate to severe 
COPD, the combination of umeclidinium/
vilanterol, a LABA, administered once daily 
resulted in a clinically significant improve-
ment in FEV
1
 (167 mL; P<.001) vs place-
bo—but was not significantly better than 
treatment with either agent alone.18 
Few studies have evaluated time 
to exacerbation in patients receiving 
aclidinium or umeclidinium. In com-
parison to salmeterol, tiotropium re-
duced the time to first exacerbation by 
42 days at one year (hazard ratio=0.83; 95% 
confidence interval [CI], 0.77-0.9; P<.001).19 
The evidence suggests that when used in 
combination with LABAs, long-acting IACs 
have a positive impact on FEV
1
, but their 
effect on exacerbation rates has not been 
established. 
Combination therapy 
with steroids and LABAs
The combination of inhaled corticosteroids 
(ICS) and LABAs has been found to improve 
FEV
1
 and symptoms in patients with moder-
ate to severe COPD more than monotherapy 
with either drug class.20,21  In fact, ICS alone 
have not been proven to slow the progression 
of the disease or to lower mortality rates in 
patients with COPD.22  
Fluticasone/salmeterol demonstrated a 
25% reduction in exacerbation rates com-
pared with placebo (P<.0001), a greater re-
duction than that of either drug alone.20 A 
retrospective observational study compar-
ing fixed dose fluticasone/salmeterol with 
TABLE 2  
GOLD classification of severity of airflow limitations3
budesonide/formoterol reported a similar 
reduction in exacerbation rates, but the num-
ber of patients requiring the addition of an 
IAC was 16% lower in the latter group.23  
The combination of fluticasone/vilanter-
ol has the potential to improve adherence, 
given that it is dosed once daily, unlike other 
COPD combination drugs. Its clinical efficacy 
is comparable to that of fluticasone/salme-
terol after 12 weeks of therapy, with similar 
improvements in FEV
1
,24 but fluticasone/
vilanterol is associated with an increased risk 
of pneumonia.3
Chronic use of oral corticosteroids 
Oral corticosteroids (OCS) are clinically indi-
cated in individuals whose symptoms continue 
despite optimal therapy with inhaled agents 
that have demonstrated efficacy. Such patients 
are often referred to as “steroid dependent.” 
While OCS are prescribed for both their 
anti-inflammatory activity and their ability 
to slow the progression of COPD,25,26 no well-
designed studies have investigated their ben-
efits for this patient population. One study 
concluded that patients who were slowly 
withdrawn from their OCS regimen had no 
more frequent exacerbations than those who 
maintained chronic usage. The withdrawal 
group did, however, lose weight.27 
GOLD guidelines do not recommend 
OCS for chronic management of COPD due 
to the risk of toxicity.3 The well-established 
adverse effects of chronic OCS include hy-
perglycemia, hypertension, osteoporosis, 
and myopathy.28,29 A study of muscle function 
in 21 COPD patients receiving corticosteroids 
revealed decreases in quadriceps muscle 
strength and pulmonary function.30  Daily use 
Long-acting 
inhaled  
anticholinergic
agents—when 
used in  
combination 
with LABAS— 
have a positive 
effect on FEV1, 
but their effect 
on exacerbation 
rates has  
not been  
established. 
in patients with feV1/fVc <0.70
class 1 mild feV1 >80% predicted
class 2 moderate feV1 >50% to <80% predicted
class 3 Severe feV1 >30% to <50% predicted
class 4 Very severe feV1 <30% predicted 
feV1, forced expiratory volume in one second; fVc, forced vital capacity; Gold, Global initiative for chronic obstructive 
lung disease. 
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of OCS will likely result in additional therapies 
to control drug-induced conditions, as well—
another antihypertensive secondary to fluid 
retention caused by chronic use of OCS in pa-
tients with high blood pressure, for example, 
or additional medication to control elevated 
blood glucose levels in patients with diabetes.  
Phosphodiesterase-4 inhibitors 
The recommendation for roflumilast in pa-
tients with GOLD Class 2 to 4 symptoms re-
mains unchanged since the introduction of this 
agent as a treatment option for COPD.3  Phos-
phodiesterase-4 (PDE-4) inhibitors such as 
roflumilast reduce inflammation in the lungs 
and have no activity as a bronchodilator.31,32 
Roflumilast has been shown to im-
prove FEV
1 
in patients concurrently receiv-
ing a long-acting bronchodilator and to 
reduce exacerbations in steroid-depen-
dent patients, a recent systematic review of 
29 PDE-4 trials found.33 Patients taking roflu-
milast, however, suffered from more adverse 
events (nausea, appetite reduction, diarrhea, 
weight loss, sleep disturbances, and head-
ache) than those on placebo.33 
Antibiotics   
GOLD guidelines do not recommend the use 
of antibiotics for patients with COPD, except 
TABLE 3  
Recommended therapies based on GOLD classification3
in one study, 
patients slowly 
withdrawn  
from oral  
corticosteroids 
had no more  
frequent  
exacerbations 
than those who 
maintained 
chronic usage. 
category characteristics first-line therapies
A (class 1 and 2) low risk, less symptoms Pulmonary rehabilitation
and 
short-acting iac 
or
SaBa
B (class 1 and 2) low risk, more symptoms Therapies for category a
and
long-acting iac  
or
laBa 
C (class 3 and 4) high risk, less symptoms Therapies for category a
and
icS + laBa
or 
long-acting iac  
D (class 3 and 4) high risk, more symptoms Therapies for category a
and
icS + laBa
and/or 
long-acting iac 
and/or 
Pde-4 inhibitor
Gold, Global initiative for chronic obstructive lung disease; iac, inhaled anticholinergic; icS, inhaled corticosteroid; laBa, 
long-acting beta2-agonist; Pde-4, phosphodiesterase-4; SaBa, short-acting beta2-agonist.
COPD
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Patients with 
limited mobility 
can benefit from 
non-exercise 
components of 
pulmonary  
rehabilitation.
to treat acute exacerbations.1 However, recent 
studies suggest that routine or pulsed dosing 
of prophylactic antibiotics can reduce the 
number of exacerbations.34-36 A 2013 review 
of 7 studies determined that continuous an-
tibiotics, particularly macrolides, reduced 
the number of COPD exacerbations in pa-
tients with a mean age of 66 years (odds ratio 
[OR]=0.55; 95% CI, 0.39-0.77).37  
A more recent trial randomized 92 pa-
tients with a history of ≥3 exacerbations in the 
previous year to receive either prophylactic 
azithromycin or placebo daily for 12 months. 
The treatment group experienced a signifi-
cant decrease in the number of exacerbations 
(OR=0.58; 95% CI, 0.42-0.79; P=.001).38  This 
benefit must be weighed against the poten-
tial development of antibiotic resistance and 
adverse effects, so careful patient selection is 
important.
Pulmonary rehabilitation  
has proven benefits 
GOLD, the American College of Chest Physi-
cians, the American Thoracic Society, and the 
European Respiratory Society all recommend 
pulmonary rehabilitation for patients with 
COPD.39-41 In addition to reducing morbidity 
and mortality rates—including a reduction 
in number of hospitalizations and length of 
stay and improved post-discharge recovery—
pulmonary rehabilitation has been shown to 
have other physical and psychological ben-
efits.42 Specific benefits include improved 
exercise capacity, greater arm strength and 
endurance, reduced perception of inten-
sity of breathlessness, and improved overall 
health-related quality of life.  
Key features of rehab programs
Important components of pulmonary re-
habilitation include counseling on tobacco 
cessation, nutrition, education—including 
correct inhalation technique—and exercise 
training. There are few contraindications to 
participation, and patients can derive benefit 
from both its non-exercise components and 
upper extremity training regardless of their 
mobility level. 
A 2006 Cochrane review concluded that 
an effective pulmonary rehabilitation pro-
gram should be at least 4 weeks in duration,43 
and longer programs have been shown to 
produce greater benefits.44 However, there 
is no agreement on an optimal time frame. 
Studies are inconclusive on other specific as-
pects of pulmonary rehab programs, as well, 
such as the number of sessions per week, 
number of hours per session, duration and 
intensity of exercise regimens, and staff-to-
patient ratios.
z Home-based exercise training may 
produce many of the same benefits as a for-
mal pulmonary rehabilitation program. A 
systematic review found improved qual-
ity of life and exercise capacity associated 
with patient care that lacked formal pulmo-
nary rehabilitation, with no differences be-
tween results from home-based training and 
hospital-based outpatient pulmonary reha-
bilitation programs.45
Given the lack of availability of formal re-
hab programs in many communities, home-
based training for patients with COPD is 
important to consider. 
implications for practice
What is the takeaway from this evidence-
based review? Overall, it is clear that, with the 
possible exception of the effect of once-daily 
dosing on adherence, there is little difference 
among the therapeutic agents within a par-
ticular class of medications—and that more is 
not necessarily better. Indeed, evidence sug-
gests that higher doses of LABAs may reduce 
their effectiveness, rendering them no better 
than placebo. In addition, there is no signifi-
cant difference in the rate of exacerbations in 
patients taking ICS/LABA combinations and 
those receiving IACs alone. 
Pulmonary rehabilitation should be rec-
ommended for all newly diagnosed patients, 
while appropriate drug therapies should be 
individualized based on the GOLD symp-
toms/risk evaluation categories (TABLE 3).3 
While daily OCS and daily antibiotics have 
the potential to reduce exacerbation rates, 
for example, the risks of adverse effects and 
toxicities outweigh the benefits for patients 
whose condition is stable. 
Determining the optimal treatment for 
a particular patient also requires an assess-
COPD
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TABLE 4  
Adverse effects to consider in treatment selection
medication class common adverse effects clinical impact
inhaled beta2-agonists Tachycardia, dyspepsia,  
nausea, nervousness,  
insomnia, tremor46,47
adverse effects more pronounced with 
SaBas vs laBas46,47 
inhaled anticholinergics may be an  
appropriate alternative to inhaled beta2-
agonists for patients with a history of 
anxiety, arrhythmias, dilated cardio- 
myopathy, ischemic heart disease,  
insomnia, or gastric reflux3
may be less effective in patients on 
non-selective beta-blockers3
inhaled anticholinergics dry mouth48 Poor systemic absorption following 
inhalation48
may be preferable to inhaled 
beta2-agonists for elderly patients or 
those with multiple comorbidities due to 
safety profile3,49
combination of inhaled anticholiner-
gics and smaller doses of beta2-agonists 
provide improvements in feV1 with fewer 
systemic adverse effects3
inhaled corticosteroids oral candidiasis and  
pneumonia50
immunocompromised patients and those 
with uncontrolled diabetes are at higher 
risk50
counseling on proper administration  
technique may prevent adverse effects
continuous antibiotics Gi distress (nausea, vomiting, 
diarrhea)51
 
 
antibiotic resistance51
crohn’s disease, iBS, and other conditions 
affecting Gi motility may be exacerbated 
with chronic use of macrolide 
antibiotics51 
development of antibiotic resistance 
limits choice of antimicrobials for acute 
infections
oral corticosteroids 
(daily)
hyperglycemia, hypertension, 
reduced bone mineral density, 
and muscle weakness3,27-29
Well established relationship with  
multiple chronic conditions that 
significantly impact morbidity and  
mortality3
daily oral corticosteroid use will likely 
result in additional therapies to control 
drug-induced conditions3
Pde-4 inhibitors Gi discomfort, headache, 
worsening depression, and 
weight loss33,52
most common adverse effects are  
transient52
depression is a common comorbid condi-
tion in patients with coPd. Pulmonary 
rehabilitation has been determined to 
improve symptoms of disease-associated 
depression and should be considered 
along with pharmacotherapy for depres-
sion in patients receiving Pde-4 inhibitors3
Pde-4 inhibitor use is associated with 
weight loss; functional status and stability 
should be assessed frequently to reduce 
the risk of falls3,49
coPd, chronic obstructive pulmonary disease; feV1, forced expiratory volume in one second; Gi, gastrointestinal; iBS, irritable 
bowel syndrome; laBas, long-acting beta2-agonists; Pde-4, phosphodiesterase-4; SaBas, short-acting beta2-agonists.
An effective  
pulmonary  
rehabilitation 
program should 
be at least 
4 weeks long.
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Determining 
the optimal 
treatment for 
a particular 
patient requires 
an assessment 
of comorbidities, 
including 
potential 
adverse drug 
effects.
ment of comorbidities, including potential 
adverse drug effects (TABLE 4).3,27-29,33,46-52 Se-
lection of medication should be driven by 
patient and physician preference to optimize 
adherence and clinical outcomes, although 
cost and accessibility often play a significant 
role, as well.                  JFP
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Residents: Are you getting ready for your 
family medicine certification exam?
Then check out our monthly Residents’ Rapid Review quizzes, featuring
prep questions written by the faculty of the National Family Medicine Board Review course.
This month’s questions can be found at www.jfponline.com
Registration is required. If you are not already registered, go to: jfponline.com/residents_reg
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